[{"id":"e6296b14-457a-49ec-b305-921eba77b4de","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088588","created_at":"2025-08-02T14:24:39.476Z","updated_at":"2025-08-02T14:24:39.476Z","phase":"Phase 1","brief_title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07088588","lead_sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-07-28"},{"id":"94fc6139-3248-47b5-b7ab-1c8fcba69d09","acronym":"KEYNOTE-F86","url":"https://clinicaltrials.gov/study/NCT05787587","created_at":"2023-03-28T14:05:08.346Z","updated_at":"2025-02-25T16:18:41.344Z","phase":"Phase 1","brief_title":"A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05787587 - KEYNOTE-F86","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IDE161"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-10-28"},{"id":"2aa0a94b-c8bb-4324-b8f4-5faa62cc12cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06614751","created_at":"2025-02-26T14:57:42.294Z","updated_at":"2025-02-26T14:57:42.294Z","phase":"Phase 1","brief_title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","source_id_and_acronym":"NCT06614751","lead_sponsor":"Danatlas Pharmaceuticals Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-27"},{"id":"f3a5ca6c-9dad-455e-839f-ff92f7d44bcd","acronym":"ERADIC8","url":"https://clinicaltrials.gov/study/NCT06395519","created_at":"2024-05-04T04:25:21.274Z","updated_at":"2024-07-02T16:35:06.435Z","phase":"Phase 1","brief_title":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT06395519 - ERADIC8","lead_sponsor":"858 Therapeutics, Inc.","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-02"}]